Filgotinib in Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis of Efficacy and Adverse Events.

Healthcare (Basel) · 2025 · PMC12785585 · PMID 41516937

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Biologic-naive patients showed a nominally significant improvement in clinical remission rates with filgotinib 200 mg, while biologic-experienced patients had higher rates of prior treatment failures.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.